Hanmi's New Story
Creativity, Innovation, and Challenge
A New Era Takes Off at Hanmi
Meet Us at ADA 2025.
Metabolic Adaptation of Liver with Treatment of HM15275, a Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Supporting Lean Mass Preservation
- Poster Number
- 755-P
- Session
- General Poster Session, Jun 22 at 12:30~13:30 PM
- Presenter
-
Hosun Lee /
Hanmi Pharmaceutical
Robust Anti-obesity Effect and Mechanistic Insights of HM15275, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in Animal Model of Obesity
- Poster Number
- 774-P
- Session
- General Poster Session, Jun 22 at 12:30~13:30 PM
- Presenter
-
Sang Hyun Park, Ph.D /
Hanmi Pharmaceutical
A Novel CRFR2-Selective UCN2 Analog, HM17321, Improves Glycemic Control across Multiple Preclinical Models
- Poster Number
- 842-P
- Session
- General Poster Session, Jun 22 at 12:30~13:30 PM
- Presenter
-
Seon Myeong Lee /
Hanmi Pharmaceutical
A Novel CRFR2 Selective UCN2 Analog, HM17321, Facilitates Weight Loss and Improves Body Composition across Animal Models of Obesity
- Poster Number
- 843-P
- Session
- General Poster Session, Jun 22 at 12:30~13:30 PM
- Presenter
-
Seon Myeong Lee /
Hanmi Pharmaceutical
A Novel UCN2 Analog HM17321 with HM15275 Improves Body Composition in Mouse Model of Obesity
- Poster Number
- 886-P
- Session
- General Poster Session, Jun 22 at 12:30~13:30 PM
- Presenter
-
Hyunjoo Kwon, Ph.D /
Hanmi Pharmaceutical
Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist - Preliminary Results from a Phase 1 Study
- Poster Number
- 1980-LB
- Session
- Late Breaking Poster Session, Jun 22 at 12:30~13:30 PM
- Presenter
-
Marcus Hompesch, MD /
ProSciento, Inc.
